Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
Sungjune Kim, Evan Wuthrick, Dukagjin Blakaj, Zeynep Eroglu, Claire F. Verschraegen, Ram Thapa, Matthew N. Mills, Khaled Dibs, Casey Liveringhouse, Jeffery S. Russell, Jimmy J. Caudell, Ahmad A. Tarhini, Joseph Markowitz, Kari Kendra, Richard C. Wu, Dung‐Tsa Chen, Anders Berglund, Lauren Michael, Mia Aoki, Min-Hsuan Wang, Imène Hamaidi, Pingyan Cheng, Janis V. de la Iglesia, Robbert J Slebos, Christine H. Chung, Todd C. Knepper, Carlos Moran Segura, Jonathan V. Nguyen, Bradford A. Perez, Trevor Rose, Louis B. Harrison, Jane L. Messina, Vernon K. Sondak, Kenneth Y. Tsai, Nikhil I. Khushalani, Andrew S. Brohl
Topics & Concepts
NivolumabIpilimumabMedicineMerkel cell carcinomaOncologyInternal medicineRadiation therapyMerkel cellResponse Evaluation Criteria in Solid TumorsMelanomaCancerCarcinomaPhases of clinical researchClinical trialImmunotherapyCancer researchPolyomavirus and related diseasesBacteriophages and microbial interactionsMultiple Sclerosis Research Studies